Teva Pharmaceuticals News and Resources

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has announced a new global licensing agreement with mAbxience, a Fresenius Kabi majority-owned group. This agreement focuses on the development of an anti-PD-1 oncology biosimilar candidate. It is the